Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on How Rabbit Anti-Human Thymocyte Immunoglobulin Helps Prevent Graft-versus-Host Disease in Children and Adults Undergoing Stem Cell Transplants

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a medication called Thymoglobulin in preventing a condition known as Graft-versus-Host Disease (GvHD). GvHD can occur in patients who receive a type of treatment called allogeneic hematopoietic stem cell transplantation, which is often used for various blood disorders and cancers. The study includes both children and adults who are undergoing this transplantation procedure.

The purpose of the study is to understand how Thymoglobulin, which is an anti-lymphocyte serum, behaves in the body. This medication is given as a solution through an infusion, which means it is delivered directly into the bloodstream. The study will involve monitoring patients who are receiving Thymoglobulin as part of their treatment to see how the medication is processed by the body over time.

Participants in the study will receive Thymoglobulin and may also receive a placebo. The study will track the levels of the medication in the blood and gather data to help understand its effects. This information will help improve the use of Thymoglobulin in preventing GvHD in patients undergoing stem cell transplantation.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be informed about the trial and asked to provide consent. If you are under 18, your parents or guardians will need to give their consent.

    A pregnancy test will be conducted if applicable, and you will be required to use an effective method of contraception throughout the study.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to ensure you meet the eligibility criteria, including age and health status.

    Your Lansky or Karnofsky score, which measures your ability to perform daily activities, will be evaluated.

  3. Step 3

    Treatment administration

    You will receive a medication called Thymoglobuline, which is a solution for infusion. This medication is used to prevent a condition called GvHD during your stem cell transplantation.

    The medication will be administered through an infusion, which means it will be given directly into your bloodstream.

  4. Step 4

    Monitoring and follow-up

    Throughout the study, your health and response to the medication will be closely monitored.

    Blood samples will be taken to measure the levels of the medication in your body and to assess its effects.

  5. Step 5

    Completion of the study

    Once the study period is over, a final assessment will be conducted to evaluate your overall health and the outcomes of the treatment.

    You will be informed about the results and any further steps if necessary.

Who can join the trial?

10 criteria

  • Patient receiving **Thymoglobulin** therapy as part of a first **HSC allograft**. (HSC allograft is a type of stem cell transplant.)
  • Age **2 years or older**.
  • **Lansky or Karnofsky score** of **50% or higher**. (These scores measure a patient's ability to perform daily activities.)
  • Enrolled in a **social security plan**.
  • Patient **18 years of age or older** must be informed and consent to participate in the study, or if the patient is a minor, their parents/guardians must be informed and give consent for the minor's participation.
  • Patients who can have children must use an **effective method of contraception** throughout the study. (A pregnancy test will also be done at the start of the study.) Examples of effective contraceptive methods include:
    • Bilateral tubal ligation (surgical procedure to block fallopian tubes)
    • Male sterilization
    • Hormonal contraceptives that prevent ovulation
    • Hormone-releasing intrauterine devices (IUDs)
    • Copper intrauterine devices (IUDs)

Who cannot join the trial?

9 criteria

  • Patients who have had a severe allergic reaction to **Thymoglobulin®** or any of its ingredients cannot participate.
  • Patients with a history of severe allergic reactions to other medications or treatments are not eligible.
  • Patients with active infections that are not controlled or treated cannot join the study.
  • Patients with a history of cancer, except for certain types of skin cancer, are excluded.
  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients with severe heart, liver, or kidney problems are not eligible.
  • Patients who have received another investigational drug within the last 30 days cannot join the study.
  • Patients with a history of drug or alcohol abuse in the past year are excluded.
  • Patients who are unable to follow the study procedures or attend the required visits cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Anti-lymphocyte serum (SAL)

    is a medication used to help prevent a condition called Graft-versus-Host Disease (GvHD) in patients who are receiving a type of treatment known as allogeneic hematopoietic stem cell transplantation. This condition can occur when the new stem cells attack the patient's body. The anti-lymphocyte serum works by suppressing the immune system to reduce the risk of this happening.

  • Thymoglobulin®

    is another medication used in the same context to prevent GvHD. It is an immunosuppressive drug, which means it helps to lower the activity of the immune system. By doing this, Thymoglobulin® helps to prevent the new stem cells from attacking the patient's body, making the transplantation process safer.

What is already known about the treatment

Thymoglobulin® – Thymoglobulin® is administered through an intravenous infusion, which means it is given directly into a vein. It is currently used in medical practice to help prevent a condition called Graft-versus-Host Disease (GvHD) in both children and adults who are receiving a type of treatment called allogeneic hematopoietic stem cell transplantation (HSC). This medication works by targeting and reducing the activity of certain immune cells, which helps to prevent the body from attacking the transplanted cells. Thymoglobulin® is classified as an immunosuppressive agent, meaning it helps to suppress or reduce the strength of the body's immune response.

Investigated diseases

Hematopoietic Stem Cell Transplantation – This procedure involves the transplantation of blood stem cells to replace damaged or diseased bone marrow. It is used to treat certain cancers, blood disorders, and immune system conditions. The process begins with the collection of healthy stem cells from a donor, followed by the administration of high-dose chemotherapy or radiation therapy to the patient. The healthy stem cells are then infused into the patient's bloodstream, where they travel to the bone marrow and begin to produce new blood cells. Over time, the transplanted stem cells can help restore the patient's blood cell production and immune function. The progression of recovery varies, with the initial phase focusing on engraftment and the long-term phase on immune system rebuilding.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2022-501594-39-00Protocol code69HCL21_1186Estimated enrolment35 patientsSponsorHospices Civils De Lyon

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).